Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Quarter	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020
Period Ending	Sep '26 Sep 30, 2026	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Jun '24 Jun 30, 2024	Mar '24 Mar 31, 2024	Dec '23 Dec 31, 2023	Sep '23 Sep 30, 2023	Jun '23 Jun 30, 2023	Mar '23 Mar 31, 2023	Dec '22 Dec 31, 2022	Sep '22 Sep 30, 2022	Jun '22 Jun 30, 2022	Mar '22 Mar 31, 2022	Dec '21 Dec 31, 2021	Sep '21 Sep 30, 2021	Jun '21 Jun 30, 2021	Mar '21 Mar 31, 2021	Dec '20 Dec 31, 2020
Keytruda/Keytruda Qlex Revenue	8.60B
Gardasil/Gardasil 9 Revenue	2.00B
Januvia/Janumet Revenue	380.00M
ProQuad/M-M-R II/Varivax Revenue	730.00M
Bridion Revenue	144.00M
Lynparza - Alliance Revenue	352.00M
Winrevair Revenue	694.00M
Lenvima - Alliance Revenue	287.00M
Pharmaceutical Revenue	16.27B
Animal Health Revenue	1.68B
Other Product Revenue	141.00M
Revenue (Other)	-13.18B
Revenue (Total)	18.09B